Return to NG122 Overview

Lung cancer: diagnosis and management [NG122]

Measuring the use of this guidance

Recommendation: 1.2.2

Ensure that a lung cancer clinical nurse specialist is available at all stages of care to support people and (as appropriate) their family members or carers.

What was measured: Proportion of people with lung cancer who were assessed by a lung cancer nurse specialist.
Data collection end: August 2018
70%
Area covered: National
Source: Royal College of Physicians. National lung cancer audit.


Recommendation: 1.3.11

When taking samples, ensure they are adequate (without unacceptable risk to the person) to permit pathological diagnosis, including tumour subtyping and assessment of predictive markers.

What was measured: Proportion of people with stage I–II lung cancer who have a performance status of 0–1 and receive pathological diagnosis.
Data collection end: August 2018
89%
Area covered: National
Source: Royal College of Physicians. National lung cancer audit.


Recommendation: 1.4.20

For people with NSCLC who are well enough and for whom treatment with curative intent is suitable, offer lobectomy (either open or thoracoscopic).

What was measured: Proportion of people with histologically confirmed or presumed non-small-cell lung cancer who underwent surgery.
Data collection end: August 2018
18.4%
Area covered: National
Source: Royal College of Physicians. National lung cancer audit.


Recommendation: 1.4.32

Consider chemoradiotherapy for people with stage II or III NSCLC that are not suitable for or decline surgery. Balance potential benefit in survival with the risk of additional toxicities.

What was measured: Proportion of people with stage IIIA NSCLC and a good performance status who received chemotherapy and either surgery or radical radiotherapy.
Data collection end: August 2018
34%
Area covered: National
Source: Royal College of Physicians. National lung cancer audit.


Recommendation: 1.4.53

Offer people with limited-stage disease SCLC (broadly corresponding to T1–4, N0–3, M0) 4 to 6 cycles of cisplatin-based combination chemotherapy. Consider substituting carboplatin in people with impaired renal function, poor performance status (WHO 2 or more) or significant comorbidity.

What was measured: Proportion of people with small cell lung cancer who received chemotherapy.
Data collection end: August 2018
70%
Area covered: National
Source: Royal College of Physicians. National lung cancer audit.



 Return to NG122 Overview